ArticleFrontiers in pharmacology2025
Network pharmacology and experimental validation to elucidate the pharmacological mechanisms of OATF against kidney stones.
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Methods: Network pharmacology and molecular docking were utilized to predict the potential targets and pathways of OATF. An animal model of calcium oxalate crystal deposition was created using intraperitoneal injections of ethylene glycol (EG) and ammonium chloride (AC), alongside a model using human renal tubular epithelial cells (HK-2) induced by supersaturated oxalate (Ox) to investigate the pharmacological mechanisms of OATF against oxidative stress and apoptosis. The effects of OATF on crystal deposition and renal damage were assessed using hematoxylin-eosin (H&E) and periodic acid-Schiff (PAS) staining. Renal tubular damage and apoptosis were evaluated via TUNEL staining. The MOA was explored using Western blotting analyses. Results: Network pharmacological analysis identified the EGFR/PI3K/AKT pathway as a key mechanism in KS. Conclusion: OATF effectively inhibited kidney stone formation and mitigated renal injury by attenuating oxidative stress and apoptosis through activation of the EGFR/PI3K/AKT pathway. These findings highlight OATF's therapeutic potential for KS management and provide a scientific basis for its traditional use in herbal medicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.